Liposome Drug Delivery Market – Trends Forecast Till 2030

Market Snapshot

Market Overview

The global Liposome Drug Delivery Market size is projected to reach a CAGR of 9.8% from 2023-2030.

Liposome drug delivery is a way of administering a medication that increases its bioavailability and reduces toxicity. Liposomes are tiny vesicles made from naturally occurring molecules in the body, which can transport drugs into targeted cells for improved effectiveness while reducing side effects compared to conventional methods like intravenous injections or oral medications. The Liposome-mediated drug delivery technology is one of the most promising approaches to treating cancers and other diseases.

The growth of the market can be attributed to the rising prevalence of cancer, and therefore the need for advanced drug delivery systems for the treatment of the disease. the rising focus of healthcare researchers on developing targeted drug delivery systems (TDDS) is also expected to create numerous opportunities for market growth. Furthermore, the factors that will enhance the growth of the market are the Growing geriatric population base across the world, high unmet medical needs owing to the increasing number of drug-resistant diseases, and increased use of liposomes for therapeutic purposes due to their advantages over other delivery systems such as injection, oral pill formulations.

On the other hand, High production cost is the major reason behind the hindrance of market growth. Additionally, low solubility and short half-life of liposomes can negatively affect the preference rate, hindering the growth of the Liposomes Drug Delivery Market.

An increase has been witnessed in the demand for medical supplies to take care of the infected population. Respiratory support devices such as atomizers, life support machines, oxygen generators, and monitors are among the majorly used medical devices in primary clinical treatment. Moreover, COVID-19 has led to a huge surge in demand for medical supplies such as personal protective equipment including masks, gloves, and protective eyeglasses. The need for medical supplies has increased significantly among both healthcare professionals and the civil population for precautionary measures, owing to the rise in the number of COVID-19 cases worldwide. Manufacturers of these products have a chance to capitalize on this increased demand for medical supplies to ensure an adequate and continuous supply of personal protective equipment in the market. Therefore, COVID-19 is expected to have a significant impact on the global liposome drug delivery market.

Delvens Industry Expert's Standpoint

In the upcoming years, the desire for targeted drug delivery, the prevalence of chronic illnesses, and developments in liposome technology are projected to generate a large increase in the market for liposome drug delivery. Although there are many businesses operating in the industry, which is extremely fragmented, it is also fiercely competitive, with a few significant firms controlling the majority of the market share. The market is anticipated to be dominated by North America and Europe, but the Asia-Pacific region is anticipated to have considerable growth because of increased healthcare spending and the prevalence of chronic illnesses there. Johnson & Johnson, Pfizer, Inc., Gilead Sciences, Inc., Teva Pharmaceutical Industries Ltd., and Sun Pharmaceutical Industries Ltd. are a few of the market's top competitors. In the upcoming years, consolidation is predicted to continue as bigger competitors buy smaller rivals to broaden their product lines and boost their market share.

Market Portfolio

Key Findings

• The product segment is further fragmented into liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, and others. liposomal doxorubicin accounted for the largest share and is anticipated to maintain its dominance over the forecast period owing to the high efficacy of the drug exhibited in the treatment of cancer. Moreover, liposomal doxorubicin is beneficial over its traditional counterpart in terms of toxicity and targeted drug delivery.

• The technology segment is further fragmented into Stealth Liposome Technology, Non-PEGylated Liposome Technology, DepoFoam Liposome Technology, and Lysolipid Thermally Sensitive Liposome (LTSL) Technology. The stealth liposome technology segment held the largest share of the market in 2021 and is likely to continue to register the highest CAGR in the market during the forecast period.
   
• The application segment is further segmented into fungal diseases, cancer therapy, pain management, viral vaccines, and photodynamic therapy. The cancer therapy segment held the largest share of the market in 2022 and is likely to continue to register the highest CAGR in the market during the forecast period.
   
• The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. The market in North America is projected to be the largest revenue share and is anticipated to maintain its dominance over the forecast period.

Regional Analysis

North America to Dominate the Market

• The market in North America is projected to be the largest revenue share and is anticipated to maintain its dominance over the forecast period.
   
• The growth of the market in the region can primarily be attributed to the increasing prevalence of cancer in the region, followed by the surge in government initiatives that promote research and development for cancer drugs and drug delivery systems, along with the surge in healthcare expenditure in the region.

Competitive Landscape

• Johnson and Johnson
• Gilead Sciences
• Pacira
• Sun Pharmaceutical
• Luye Pharma
• Sigma-Tau Group
• Fudan-Zhangjiang
• Teva Pharmaceutical
• CSPC
• Novartis
• Kingond Pharm
• Spectrum Pharmaceuticals
• Shanghai New Asia

Recent Developments

• June 17th, 2020: Ipsen Pharma announced that it has received the Fast Track designation by the United States Food and Drug Administration (FDA) for the investigational use of liposomal irinotecan (ONIVYDE) in combination with oxaliplatin (OX) and 5-fluorouracil/leucovorin (5-FU/LV) together.
   
• December 9th, 2019: FUJIFILM Toyama Chemical Co., Ltd. announced that it has completed its first manufacturing facility named 701 for liposome formulation in Japan.

Reasons to Acquire

• Increase your understanding of the market for identifying the best and suitable strategies and decisions on the basis of sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends and factors.
   
• Gain authentic and granular data access for Liposome Drug Delivery Market so as to understand the trends and the factors involved behind changing market situations.
   
• Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.
   
• In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Report Scope